PL2554541T3 - Środek terapeutyczny lub środek profilaktyczny na fibromialgię - Google Patents
Środek terapeutyczny lub środek profilaktyczny na fibromialgięInfo
- Publication number
- PL2554541T3 PL2554541T3 PL11765736T PL11765736T PL2554541T3 PL 2554541 T3 PL2554541 T3 PL 2554541T3 PL 11765736 T PL11765736 T PL 11765736T PL 11765736 T PL11765736 T PL 11765736T PL 2554541 T3 PL2554541 T3 PL 2554541T3
- Authority
- PL
- Poland
- Prior art keywords
- agent
- fibromyalgia
- prophylactic
- therapeutic agent
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010083721 | 2010-03-31 | ||
EP11765736.1A EP2554541B1 (en) | 2010-03-31 | 2011-03-31 | Therapeutic agent or prophylactic agent for fibromyalgia |
PCT/JP2011/058218 WO2011125836A1 (ja) | 2010-03-31 | 2011-03-31 | 線維筋痛症の治療剤又は予防剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2554541T3 true PL2554541T3 (pl) | 2016-06-30 |
Family
ID=44762774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11765736T PL2554541T3 (pl) | 2010-03-31 | 2011-03-31 | Środek terapeutyczny lub środek profilaktyczny na fibromialgię |
Country Status (13)
Country | Link |
---|---|
US (1) | US8957094B2 (pl) |
EP (1) | EP2554541B1 (pl) |
JP (1) | JP5751168B2 (pl) |
KR (1) | KR101738471B1 (pl) |
CN (1) | CN102822148B (pl) |
AU (1) | AU2011237072B2 (pl) |
BR (1) | BR112012022947B1 (pl) |
CA (1) | CA2793709C (pl) |
ES (1) | ES2562470T3 (pl) |
MX (1) | MX2012010767A (pl) |
PL (1) | PL2554541T3 (pl) |
RU (1) | RU2560168C2 (pl) |
WO (1) | WO2011125836A1 (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2560220T3 (es) * | 2010-04-28 | 2016-02-17 | Toray Industries, Inc. | Agente terapéutico y agente preventivo para la enfermedad de Alzheimer |
CA2805371C (en) | 2010-07-30 | 2017-10-31 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
JPWO2014088106A1 (ja) * | 2012-12-06 | 2017-01-05 | 株式会社PRISM Pharma | 線維筋痛症の予防または治療薬 |
BR112016016674A2 (pt) | 2014-01-29 | 2017-08-08 | Toray Industries | Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla |
KR20180072665A (ko) * | 2015-07-28 | 2018-06-29 | 베타 캐트 파마슈티칼스, 인코포레이티드 | 안트라센-9,10-디온 디옥심 화합물 전구약물 및 이의 용도 |
US11039755B2 (en) | 2015-12-03 | 2021-06-22 | Robert S. Katz | Methods and systems for diagnosing and treating fibromyalgia |
RU2736722C2 (ru) | 2016-07-29 | 2020-11-19 | Джапан Тобакко Инк. | Способ получения соединения пиразоламида |
WO2018181859A1 (ja) * | 2017-03-31 | 2018-10-04 | 東レ株式会社 | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
US6437146B1 (en) * | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
WO2000066562A1 (en) * | 1999-05-03 | 2000-11-09 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
JP2006503025A (ja) * | 2002-09-05 | 2006-01-26 | サイオス インク. | p38MAPキナーゼの抑制による疼痛治療 |
JPWO2007111323A1 (ja) * | 2006-03-27 | 2009-08-13 | 東レ株式会社 | ウレイド誘導体およびその医薬用途 |
CN101511802A (zh) * | 2006-09-13 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途 |
US20080171762A1 (en) * | 2007-01-16 | 2008-07-17 | Ockert David M | Treatment of pain with naloxone |
WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
TWI435874B (zh) * | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
-
2011
- 2011-03-31 EP EP11765736.1A patent/EP2554541B1/en active Active
- 2011-03-31 KR KR1020127023059A patent/KR101738471B1/ko active IP Right Grant
- 2011-03-31 ES ES11765736.1T patent/ES2562470T3/es active Active
- 2011-03-31 AU AU2011237072A patent/AU2011237072B2/en not_active Ceased
- 2011-03-31 MX MX2012010767A patent/MX2012010767A/es active IP Right Grant
- 2011-03-31 RU RU2012146325/04A patent/RU2560168C2/ru not_active IP Right Cessation
- 2011-03-31 US US13/636,805 patent/US8957094B2/en active Active
- 2011-03-31 BR BR112012022947-8A patent/BR112012022947B1/pt not_active IP Right Cessation
- 2011-03-31 CA CA2793709A patent/CA2793709C/en active Active
- 2011-03-31 PL PL11765736T patent/PL2554541T3/pl unknown
- 2011-03-31 WO PCT/JP2011/058218 patent/WO2011125836A1/ja active Application Filing
- 2011-03-31 JP JP2011514905A patent/JP5751168B2/ja not_active Expired - Fee Related
- 2011-03-31 CN CN201180016967.3A patent/CN102822148B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2012146325A (ru) | 2014-05-10 |
JP5751168B2 (ja) | 2015-07-22 |
KR20130052536A (ko) | 2013-05-22 |
BR112012022947A2 (pt) | 2020-07-28 |
AU2011237072A1 (en) | 2012-10-18 |
AU2011237072B2 (en) | 2014-09-04 |
JPWO2011125836A1 (ja) | 2013-07-11 |
CA2793709C (en) | 2017-09-12 |
CN102822148A (zh) | 2012-12-12 |
BR112012022947B1 (pt) | 2021-06-15 |
EP2554541A4 (en) | 2013-10-09 |
EP2554541B1 (en) | 2015-12-09 |
MX2012010767A (es) | 2012-10-15 |
KR101738471B1 (ko) | 2017-05-22 |
RU2560168C2 (ru) | 2015-08-20 |
US8957094B2 (en) | 2015-02-17 |
ES2562470T3 (es) | 2016-03-04 |
CN102822148B (zh) | 2015-03-11 |
US20130190503A1 (en) | 2013-07-25 |
WO2011125836A1 (ja) | 2011-10-13 |
CA2793709A1 (en) | 2011-10-13 |
EP2554541A1 (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181615T1 (hr) | Terapijsko sredstvo koje izaziva citotoksičnost | |
HK1210031A1 (en) | Therapeutic agent or prophylactic agent for dementia | |
IL222481A0 (en) | Combination therapy | |
EP2552323A4 (en) | COMBINATION THERAPY | |
EP2671585A4 (en) | THERAPEUTIC OR PROPHYLACTIC AGGREGATE AGAINST CACHEXIA | |
PL2554541T3 (pl) | Środek terapeutyczny lub środek profilaktyczny na fibromialgię | |
EP2529739A4 (en) | THERAPEUTIC OR PROPHYLACTIC AGGREGATE AGAINST GALLERY DISEASES | |
HK1173368A1 (en) | Pigmentation-preventing or-ameliorating agent | |
PL2723344T3 (pl) | Złożony środek leczniczy zawierający monoterpen | |
IL245995A0 (en) | Prophylactic or medical agent for fibrosis | |
EP2510949A4 (en) | THERAPEUTICS FOR FIBROMYALGIA | |
EP2745838A4 (en) | PROPHYLACTIC AGENT AND / OR THERAPEUTIC AGENT FOR SEPTICEMIA | |
PL2599487T3 (pl) | Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu | |
EP2594275A4 (en) | AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF DIABETES | |
EP2629766A4 (en) | COMBINATION THERAPY | |
GB201003727D0 (en) | Therapeutic agent | |
GB201011456D0 (en) | Compositions and methods for embolization therapy |